Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. - Wikidata - awgldk - TriplyDB

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.

http://www.wikidata.org/entity/Q45246419

about

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials Newer therapies for the treatment of metastatic breast cancer: a clinical update Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors Combination of Sonodynamic and Photodynamic Therapy against Cancer Would Be Effective through Using a Regulated Size of Nanoparticles.Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer.ErbB expression, activation, and inhibition with lapatinib and tyrphostin (AG825) in human vestibular schwannomas.ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma.Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers Strategies for modern biomarker and drug development in oncology.Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.Evaluation of a novel approach to circulating tumor cell isolation for cancer gene panel analysis in patients with breast cancer.ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation.A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression Lapatinib for the treatment of breast cancer in the People's Republic of China.Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib.Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts.Targeted treatment of advanced and metastaticbreast cancer with lapatinib.Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment.Role of lapatinib in the first-line treatment of patients with metastatic breast cancer.Testing for HER2 in Breast Cancer: A Continuing Evolution.cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer The HER family and cancer: emerging molecular mechanisms and therapeutic targets.Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer Targeting the function of the HER2 oncogene in human cancer therapeutics.Phosphoproteomic analysis of Her2/neu signaling and inhibition.Urothelial carcinomas: a focus on human epidermal receptors signaling Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms.Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck.HER2: biology, detection, and clinical implications Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.Epidermal growth factor receptor in breast carcinoma: association between gene copy number and mutations.

P2860

Q24633878-4F2ABF2D-095A-49B9-9A33-37626F38A8C0 Q26747729-42D6BA9E-60F2-493D-9C1B-91D42B71D874 Q26777733-614475B5-F40A-4A97-A4F8-130AC4FA5A7F Q26827936-7D994A24-2156-4625-B079-1693FA749C75 Q26865260-B2F4149E-92F7-4D86-B0C3-F1149EBA716D Q27342948-9560B451-9329-46F0-9128-258B72C4956F Q28292264-7EBF636B-3739-4441-80DE-36FDE7F67720 Q30364639-ADB0A03D-E039-456F-937A-4F24486E5D0B Q30438089-87CDD7DA-0794-494A-ACB3-24FDA5B4D13B Q30457869-DE074DA5-EDDE-45ED-BD2B-58A5434917C3 Q30474678-D46BC609-660D-4E32-B6E1-FEC74838342C Q30579903-D0864926-6A25-4F2B-BB9D-CB07229BBDE1 Q30590270-AA66E596-8D4F-4E73-B308-98D31B1DA51E Q33528957-D8F7D17B-A487-49CC-A5CC-4845ADD2377C Q33597447-56DD729D-C298-412D-B2C8-D695374DC131 Q33638654-AE399C9B-D58D-4FF9-B775-51A63757F766 Q33684887-51E6FC85-93DF-436B-BEAB-FD528F415186 Q33811642-0A5AFD5A-62AF-4903-8E28-E60D440BED58 Q33991817-F4AEE6B8-94C5-45D4-A26B-36A2D6515494 Q34016491-1813346A-3A82-479A-9CA1-201FBD245EF9 Q34158454-A9EA70C8-970F-4C46-97F1-3D01153E01C2 Q34241118-191D5BE3-F88C-46A6-A358-F4CDFF2E8301 Q34291564-8ED6DFDC-E72E-40F8-BF9E-2802DC708E8A Q34363419-951719E4-8094-43F1-9CD1-A8C8FE3BBD7C Q34385041-86D75CA5-1281-43DB-882A-17EFECD5C2CA Q34417920-D6ED5904-2F62-42FF-B7C7-D94961C4AD55 Q34424285-C32AC5DB-7F8F-4FA7-8A00-DC6BC4815385 Q34438708-63A07DF3-900E-4E8F-99A1-C89EF680B0BC Q34558080-615E418C-0DDD-4933-98AA-D0C851ADA8D0 Q34570753-0453D630-70F7-4D6C-87A9-667BEC811497 Q34611634-59FE0D90-2615-4A6E-94C7-86F96F52AD4C Q34650878-D4A550C5-3098-4283-B29A-170388E74A3B Q34766486-859983F1-F215-4CA5-9E72-C8BD5127074A Q34772747-46A9891A-6E39-468B-A95A-6E571FCD40F4 Q35172558-82EE207D-62D3-42E5-A3D4-247EEE63A112 Q35219426-EDB51E11-36B2-44E2-879C-5EBF6FB82361 Q35287729-CEECA75F-00AC-4DE4-9A92-7B4CC0F00F9F Q35622862-29E2DCEB-0A24-4852-BA45-9FBD675013AE Q35625995-98661342-8D7F-436D-9D70-B784195B73BE Q35642677-FB3F5FFA-0F77-4F9A-BAD3-98E011D04E55

P2860

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.

http://www.wikidata.org/entity/Q45246419

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Study of the biologic effects ...... ts with advanced malignancies.

@en

Study of the biologic effects ...... ts with advanced malignancies.

@nl

type

label

Study of the biologic effects ...... ts with advanced malignancies.

@en

Study of the biologic effects ...... ts with advanced malignancies.

@nl

prefLabel

Study of the biologic effects ...... ts with advanced malignancies.

@en

Study of the biologic effects ...... ts with advanced malignancies.

@nl

P1433

Q45246419-50AA4F0E-500F-4BAD-9E3E-3E14C94DC400

P1476

Q45246419-6C7DCF06-632A-4500-B902-11B3EDFF5557

P2093

Q45246419-2AD6FE4A-F84C-41E5-8ACE-921AC3FDDE25

Q45246419-2CC8DD33-798D-4630-82C2-739614B29F53

Q45246419-3BA2890B-F29D-4F3A-A96F-561F64245EA0

Q45246419-63441A4E-BBD7-485B-A341-15BFFE7D684C

Q45246419-697B0923-6F2C-48D1-B312-D119F2D4AB5C

Q45246419-6C865E8F-BB5D-4EEB-8DC9-2EEA102489E7

Q45246419-7B47C5D5-A8AF-42C1-BF6B-426D47A02B39

Q45246419-87B6DE14-58D0-4BC3-8838-064FF55FACAD

Q45246419-87BB2A00-E5A6-4E1E-8558-34E2EC10413B

Q45246419-8BED9B19-F3A4-4DB3-818C-B98883F80CF9

P304

Q45246419-A7277E55-FCEB-4AB0-8C22-60AFE6BC7A36

P31

Q45246419-E66A6939-31FB-4811-B58C-C09B785EE845

P356

Q45246419-BA5865F5-3E93-414D-B973-96D46D12DDB7

P407

Q45246419-0DBA4BE5-A847-4987-8C1E-012472F83D64

P433

Q45246419-A03DD64E-946E-4424-A01B-F50B02B047CD

P478

Q45246419-D75B7F7E-7A9A-4E75-86C3-AD2E7CC8BA9D

P577

Q45246419-F4E9BB87-C764-4067-BF66-7C17DBE96107

P698

Q45246419-77283E33-FFF4-43E9-A3E9-37BEFBC9EB08

P921

Q45246419-5DD3B4DA-6580-4DA0-B2AC-514739D37D38

P356

JCO.2005.12.157

P1433

Journal of Clinical Oncology

P1476

Study of the biologic effects ...... ts with advanced malignancies.

@en

P2093

Afshin Dowlati

http://www.w3.org/2001/XMLSchema#string

Albert K Man

http://www.w3.org/2001/XMLSchema#string

Andrew Stead

http://www.w3.org/2001/XMLSchema#string

Bert O'Neil

http://www.w3.org/2001/XMLSchema#string

Beth Overmoyer

http://www.w3.org/2001/XMLSchema#string

Deborah A Smith

http://www.w3.org/2001/XMLSchema#string

E Claire Dees

http://www.w3.org/2001/XMLSchema#string

Herbert Hurwitz

http://www.w3.org/2001/XMLSchema#string

Howard Burris

http://www.w3.org/2001/XMLSchema#string

Jennifer Harris

http://www.w3.org/2001/XMLSchema#string

P304

2502-2512

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.12.157

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2005-01-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15684311

http://www.w3.org/2001/XMLSchema#string

P921